Drugs / ART6043
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05898399 | Jun 2023 → Jun 2028 expected | metastatic neoplasm, neoplasm | Artios Pharma Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-02-23 | Artios Pharma Ltd | Regulatory Artios Receives U.S. FDA Fast Track Designation for DNA Polymerase Theta (Polθ) Inhibitor ART6043 for Treatment of gBRCA-mutated HER2-Negative Breast Cancer artios.com ↗ |
| 2025-10-17 | Artios Pharma Ltd | Results Artios Announces Phase 1/2a Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO Congress 2025 artios.com ↗ |
| 2025-04-15 | Artios Pharma Ltd | Results Artios Pharma Announces Details of Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 artios.com ↗
DNA polymerase theta inhibitor, ART6043, potentiates the efficacy of 177Lu- and 225Ac-based radioligand therapies in vitro and in vivo |
All press releases naming this drug 5 releases
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ART6043 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05898399 ↗ |
| Action | Inhibit | “ART6043 inhibits Polθ with low nmol/L potency” PMID 42440368 ↗ Jul 2026 |
| Modality | Small molecule | “a potent, selective, allosteric, small-molecule inhibitor of the polymerase function of Polθ.” PMID 42440368 ↗ Jul 2026 |
| Route | Oral | “ART6043 will be given orally.” NCT05898399 ↗ |
| Target | POLQ | “a potent, selective, allosteric, small-molecule inhibitor of the polymerase function of Polθ.” PMID 42440368 ↗ Jul 2026 |